US Stock MarketDetailed Quotes
AVTX Avalo Therapeutics
- 11.1500
- +0.3600+3.34%
Close May 23 16:00 ET
- 10.8800
- -0.2700-2.42%
Post 18:43 ET
11.53MMarket Cap-218P/E (TTM)
11.3000High10.3100Low26.06KVolume10.6300Open10.7900Pre Close282.60KTurnover3.33%Turnover RatioLossP/E (Static)1.03MShares1130.400052wk High-0.10P/B8.73MFloat Cap3.950152wk Low--Dividend TTM782.85KShs Float22031.7120Historical High--Div YieldTTM9.18%Amplitude3.9501Historical Low10.8450Avg Price1Lot Size
Avalo Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 0 | -89.34%1.92M | -36.27%571K | -98.42%236K | -37.75%643K | -59.51%475K | 234.40%18.05M | 309.13%896K | 1,007.33%14.95M | -69.21%1.03M |
| Operating revenue | --0 | -89.34%1.92M | -36.27%571K | -98.42%236K | -37.75%643K | -59.51%475K | 234.40%18.05M | 309.13%896K | 1,007.33%14.95M | -69.21%1.03M |
| Cost of revenue | -114.52%-80K | -62.61%1.28M | -135.65%-221K | -53.22%247K | -54.82%708K | -23.47%551K | 130.32%3.43M | 46.23%620K | -41.85%528K | 1,787.95%1.57M |
| Gross profit | 205.26%80K | -95.62%640K | 186.96%792K | -100.08%-11K | 87.83%-65K | -116.78%-76K | 274.12%14.62M | 234.63%276K | 3,162.67%14.42M | -116.32%-534K |
| Operating expense | -39.09%5.31M | -53.74%24.08M | -50.25%4.54M | -63.79%3.74M | -37.27%7.09M | -59.09%8.72M | -39.50%52.06M | -48.58%9.13M | -38.92%10.33M | -44.64%11.29M |
| Selling and administrative expenses | 17.91%3.19M | -50.27%10.3M | -9.56%2.68M | -24.18%2.49M | -12.82%2.43M | -76.82%2.71M | -16.01%20.71M | -50.53%2.96M | -44.58%3.28M | -62.40%2.78M |
| -Selling and marketing expense | -46.15%7K | -56.58%33K | -41.67%7K | 16.67%7K | -50.00%7K | -69.77%13K | -95.41%76K | -98.04%12K | -98.76%6K | -96.76%14K |
| -General and administrative expense | 18.22%3.19M | -50.24%10.27M | -9.43%2.67M | -24.25%2.48M | -12.64%2.42M | -76.85%2.7M | -10.29%20.64M | -45.10%2.95M | -39.79%3.28M | -60.27%2.77M |
| Research and development costs | -64.78%2.12M | -55.97%13.78M | -69.75%1.87M | -82.26%1.25M | -45.26%4.66M | -37.31%6.01M | -47.68%31.31M | -46.38%6.17M | -33.26%7.04M | -32.29%8.51M |
| Depreciation amortization depletion | ---- | --0 | --0 | --0 | --0 | ---- | -97.55%38K | --0 | --0 | --0 |
| -Depreciation and amortization | ---- | --0 | --0 | --0 | --0 | ---- | -97.55%38K | --0 | --0 | --0 |
| Operating profit | 40.53%-5.23M | 37.38%-23.44M | 57.64%-3.75M | -191.58%-3.75M | 39.55%-7.15M | 57.84%-8.79M | 54.42%-37.44M | 50.70%-8.86M | 124.87%4.1M | 30.95%-11.83M |
| Net non-operating interest income expense | 110.54%100K | 18.06%-3.42M | 108.54%81K | -72.94%-1.55M | 13.69%-996K | 18.82%-949K | -74.40%-4.17M | 19.85%-949K | 8.83%-898K | -382.85%-1.15M |
| Non-operating interest income | --100K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Non-operating interest expense | ---- | -18.06%3.42M | -108.54%-81K | 72.94%1.55M | -13.69%996K | -18.82%949K | 74.40%4.17M | -19.85%949K | -8.83%898K | 382.85%1.15M |
| Other net income (expense) | -56,285.44%-116.15M | -23,245.00%-4.67M | -4.51M | 83K | -40K | -930.00%-206K | 0.00%-20K | 0 | ||
| Gain on sale of security | -44,008.89%-79.4M | ---720K | ---600K | --100K | ---40K | ---180K | ---- | ---- | ---- | ---- |
| Special income (charges) | ---36.76M | ---3.91M | ---- | ---- | ---- | --0 | --0 | ---- | ---- | ---- |
| -Less：Restructuring and merger&acquisition | --9.22M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| -Less:Impairment of capital assets | ---- | --3.91M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- |
| -Less:Other special charges | --27.54M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Other non- operating income (expenses) | ---- | -110.00%-42K | --0 | ---17K | ---- | -30.00%-26K | 0.00%-20K | --0 | ---- | ---- |
| Income before tax | -1,119.29%-121.28M | 24.26%-31.53M | 16.60%-8.18M | -263.28%-5.22M | 36.94%-8.19M | 54.87%-9.95M | 50.76%-41.63M | 48.80%-9.8M | 118.31%3.2M | 25.27%-12.98M |
| Income tax | -12.50%7K | -50.00%14K | -212.50%-9K | 60.00%8K | 40.00%7K | -11.11%8K | 114.29%28K | 150.00%8K | -37.50%5K | 102.51%5K |
| Net income | -1,118.38%-121.29M | 24.28%-31.54M | 16.75%-8.17M | -263.78%-5.23M | 36.91%-8.19M | 54.85%-9.96M | 50.63%-41.66M | 48.89%-9.81M | 118.35%3.19M | 24.07%-12.99M |
| Net income continuous Operations | -1,118.38%-121.29M | 24.28%-31.54M | 16.75%-8.17M | -263.78%-5.23M | 36.91%-8.19M | 54.85%-9.96M | 50.61%-41.66M | 48.71%-9.81M | 118.27%3.19M | 24.38%-12.99M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | -1,118.38%-121.29M | 24.28%-31.54M | 16.75%-8.17M | -263.78%-5.23M | 36.91%-8.19M | 54.85%-9.96M | 50.63%-41.66M | 48.89%-9.81M | 118.35%3.19M | 24.07%-12.99M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | -1,118.38%-121.29M | 24.28%-31.54M | 16.75%-8.17M | -263.78%-5.23M | 36.91%-8.19M | 54.85%-9.96M | 50.63%-41.66M | 48.89%-9.81M | 118.35%3.19M | 24.07%-12.99M |
| Basic earnings per share | 30.88%-141 | 89.28%-114 | 95.92%-10.1878 | -132.35%-26.4 | 57.25%-141.6 | 63.83%-204 | 55.49%-1.06K | 46.16%-249.4 | 116.35%81.6 | 34.60%-331.2 |
| Diluted earnings per share | 30.88%-141 | 89.28%-114 | 95.92%-10.1878 | -132.35%-26.4 | 57.25%-141.6 | 63.83%-204 | 55.49%-1.06K | 46.16%-249.4 | 116.35%81.6 | 34.60%-331.2 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg